We're trying to set the stage for integrating these ideas" Anthony Vella, professor and Boehringer Ingelheim Chair in ...

No new safety signals were identified, with treatment-related adverse ... to induce immunogenic cell death of tumor cells. The RMAT designation is intended to expedite the development and review ...

BlueRock Therapeutics accelerates Parkinson’s stem cell therapy bemdaneprocel into phase 3 trials BlueRock ... into research and development on regenerative medicine, while billions more has been ...

A new Stanford Medicine-led study shows that CAR-T cell therapy causes mild cognitive ... including this newly recognized syndrome of immunotherapy-related cognitive impairment, so we can develop ...

Our goal for the past decade has been to make regenerative therapies the highest quality possible along with being the most affordable in the world.” — David Greene, MD, PhD, MBA SCOTTSDALE ...

Despite political headwinds through administrations from Bush to Trump, the Yale Stem Cell Center has emerged as a global leader in regenerative medicine ... cause distinct and common phenotypes ...

The publication, which is available online, confirms that 18 months following surgery, treatment with bemdaneprocel did not cause any serious adverse events related to cell therapy. In addition ...

Kennedy Jr. on Saturday, seeking records related to a list of actions it ... cosmetics oversight, cell and gene therapy approvals and cancer treatments. Lars Lokke Rasmussen, Denmark’s foreign ...

N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related ...

The primary outcome was the incidence and severity of cell therapy-related adverse events (AEs); secondary outcome ... which were then cultured under a patented regenerative cell cloning (R-Clone) ...